Venus Remedies' Q3 FY 2025-26 Quarterly Results
- 30 Jan 2026
Result Summary
- Venus Remedies Ltd reported a 6.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.2%.
- Its expenses for the quarter were down by 11.1% QoQ and 8.9% YoY.
- The net profit increased 27.1% QoQ and increased 30.5% YoY.
- The earnings per share (EPS) of Venus Remedies Ltd stood at 19.14 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 182.78 | 194.46 | 178.89 | -6.0% | 2.2% |
Total Expenses | 149.31 | 167.97 | 163.92 | -11.1% | -8.9% |
Profit Before Tax | 33.47 | 26.49 | 24.88 | 26.3% | 34.5% |
Tax | 7.89 | 6.36 | 5.28 | 24.1% | 49.4% |
Profit After Tax | 25.58 | 20.13 | 19.60 | 27.1% | 30.5% |
Earnings Per Share | 19.14 | 15.06 | 14.66 | 27.1% | 30.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Venus Remedies Ltd is a pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical products. The company operates primarily in the healthcare industry and is known for its focus on innovative drug formulations and novel therapeutic solutions. While specific recent developments are not part of the provided data, Venus Remedies has historically been involved in producing a wide range of pharmaceutical products, including antibiotics and oncology drugs. The company has a significant presence in both domestic and international markets, leveraging its research and development capabilities to sustain its competitive advantage in the pharmaceutical sector. Any additional recent developments or strategic initiatives are not available in the data provided.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Venus Remedies Ltd reported a total income of ₹182.78 crores. This represents a decrease of 6.0% compared to the previous quarter (Q2FY26), where the total income was ₹194.46 crores. However, when compared to the same quarter in the previous fiscal year (Q3FY25), there is a 2.2% increase, as the total income then was ₹178.89 crores. These figures highlight the company's revenue trends over the specified periods, showing both a decline on a quarter-over-quarter basis and a moderate growth on a year-over-year basis.
Profitability
The company's profitability metrics indicate a positive trend in Q3FY26. Profit Before Tax (PBT) increased to ₹33.47 crores, marking a significant quarter-over-quarter rise of 26.3% from ₹26.49 crores in Q2FY26 and a year-over-year increase of 34.5% from ₹24.88 crores in Q3FY25. The tax expense for Q3FY26 was ₹7.89 crores, up 24.1% from Q2FY26's ₹6.36 crores and 49.4% from Q3FY25's ₹5.28 crores. Profit After Tax (PAT) for the quarter was ₹25.58 crores, reflecting a 27.1% increase sequentially and a 30.5% rise compared to the same quarter last year. These profitability metrics underscore the financial performance of Venus Remedies Ltd in terms of profit generation.
Operating Metrics
Earnings Per Share (EPS) for Q3FY26 was ₹19.14, which is a 27.1% increase from ₹15.06 in Q2FY26 and a 30.6% increase from ₹14.66 in Q3FY25. These figures show the company’s earnings performance per share over the specified periods, indicating growth. Total expenses for Q3FY26 were ₹149.31 crores, showing a decrease of 11.1% quarter-over-quarter from ₹167.97 crores and an 8.9% decrease year-over-year from ₹163.92 crores. These operating metrics provide insight into the company's cost management and earnings efficiency. The analysis of these metrics is based solely on the data provided and does not incorporate any assumptions or external information.